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The prognostic relevance of epigenetic modifying genes (DNMT3A, TET2, and IDH1/2) in patients with acute
myeloid leukemia (AML) has been investigated extensively. However, the prognostic implications of these
mutations after allogeneic hematopoietic cell transplantation (HCT) have not been evaluated comprehen-
sively in patients with normal-karyotype (NK)-AML. A total of 115 patients who received allogeneic HCT for
NK-AML were retrospectively evaluated for the FLT3-ITD, NPM1, CEBPA, DNMT3A, TET2, IDH1/2, WT1, NRAS,
ASXL2, FAT1, DNAH11, and GATA2 mutations in diagnostic samples and analyzed for long-term outcomes after
allogeneic HCT. The prevalence rates for the mutations were as follows: FLT3-ITD positivity (FLT3-ITDpos)
(32.2%), NPM1 mutation (43.5%), CEBPA mutation (double) (24.6%), DNMT3A mutation (DNMT3Amut) (31.3%),
DNMT3A R882mut (18.3%), TET2mutation (8.7%), and IDH1/2mutation (16.5%). The 5-year overall survival (OS)
and event-free survival (EFS) rates were 57.3% and 58.1%, respectively. A multivariate analysis revealed that
FLT3-ITDpos (hazard ratio, [HR], 2.23; P ¼ .006) and DNMT3A R882mut (HR, 2.74; P ¼ .002) were unfavorable
prognostic factors for OS. In addition, both mutations were signiﬁcant risk factors for EFS and relapse. People
with DNMT3A R882mut accompanied by FLT3-ITDpos had worse OS and EFS, and higher relapse rates than
those with the other mutations, which were conﬁrmed in a propensity score 1:2 matching analysis. These
results suggest that DNMT3A R882mut, particularly when accompanied by FLT3-ITDpos, is a signiﬁcant prog-
nostic factor for inferior transplantation survival outcome by increasing relapse risk, even after allogeneic
HCT.
 2016 American Society for Blood and Marrow Transplantation.dgments on page 69.
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DNA methylation is a critical process in development,
differentiation, genomic stability, X-inactivation, and
imprinting, as it regulates the expression of speciﬁc genes
[1,2]. Novel recurrent mutations involved in DNA methyl-
ation have been detected in patients with acute myeloid
leukemia (AML) [3,4]. Transfer of the methyl group from S-
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methyltransferases (DNMTs) during cell replication [2].
DNMT3A belongs to a family of DNMTs, including DNMT1,
DNMT3A, and DNMT3B. DNMT3A is speciﬁcally involved in de
novo DNA methylation and functions independently during
replication [1,5].DNMT3Amutation (DNMT3Amut) is observed
in 14% to 34% of patients with AML and in 23% to 37% of those
with normal-karyotype (NK) AML [1,6-8]. DNMT3Amut have
also been found in patients in relapsed states, suggesting that
these mutations occur early in clonal evolution [1,9-14].
Other epigenetic modiﬁers that can be mutated in
AML include ten-eleven-translocation oncogene family
member 2 (TET2) and isocitrate dehydrogenase 1/2 (IDH1/2).
TET2 demethylates DNA, and TET2 mutations are leukemo-
genic in animal models [15]. A TET2 mutation (TET2mut)
occurs in 7% to 23% of patients with AML [16-19]. IDH1/2
are enzymes in the citric acid cycle that catalyze conversion
of isocitrate to a-ketoglutarate (a-KG) [3,20]. These muta-
tions confer a neomorphic gain of function to convert a-KG
to 2-hydroxyglutarate [4,21]. The frequency of IDH1 muta-
tion (IDH1mut) is 5.5% to 14.0% and that of IDH2 mutation
(IDH2mut) is 8.7% to 19.0% in patients with AML [22]. TET2
catalytic activity depends on a-KG, indicating that IDH1/2
mutations (IDH1/2mut) result in loss of TET2 function [18],
which may explain why IDH1/2mut are mutually exclusive
with TET2mut [3,18].
Cytogenetic and molecular markers have been adopted to
enable prognostic stratiﬁcation of AML and guide the selec-
tion of further treatment between consolidative conven-
tional chemotherapy and allogeneic hematopoietic cell
transplantation (HCT) [23]. Although mutations in the
epigenetic modifying genes (DNMT3A, TET2, and IDH1/2)
have been extensively investigated for their prognostic role
in patients with AML, their prognostic implications are
controversial. A meta-analysis reported that the DNMT3Amut
or TET2mut negatively affects the prognosis of patients with
NK-AML and that the prognostic implications of IDH1/2mut in
patients with NK-AML are unclear [8,22,24]. However, the
studies used for this meta-analysis included different patient
cohorts with a variety of cytogenetic risk groups. Several
studies have shown that fms-related tyrosine kinase 3-in-
ternal tandem duplication (FLT3-ITD) positivity (FLT3-ITDpos)
adversely affects treatment outcome in patients with AML
after allogeneic HCT because of a higher risk of early relapse
[25-27]. However, the prognostic implications of mutations
in epigenetic-modifying genes after allogeneic HCT have not
been examined in patients with NK-AML.
Herein, we evaluated the prognostic relevance of
epigenetic-modifying gene mutations (DNMT3A, TET2, and
IDH1/2) after allogeneic HCT in patients with NK-AML in the
context of survival and relapse risk.PATIENTS AND METHODS
Patients and Treatment
The enrolled patients were diagnosed from October 1998 to September
2012 at 7 institutions that had diagnostic archived samples available for
genetic study. The patient diagnostic DNA samples were routinely archived
regardless of cytogenetic results. Patients with NK-AMLwere retrospectively
selected before selecting only those patients who received initial induction
chemotherapy using a standard protocol (3-day course of anthracyclinewith
a 7-day course of cytosine arabinoside) and achieved ﬁrst complete remis-
sion (CR1) before allogeneic HCT. Patients who only received consolidative
chemotherapywere excluded. The selectionprocess is illustrated in FigureS1.
A total of 115 patients were included in the analysis. Molecular genetic
information was not used to determine the allogeneic HCT treatment mo-
dality. Patients who achieved CR received consolidation chemotherapy until
an available donor was identiﬁed. Before 2006, HLA typing at low resolutionwas used for HLA-A, -B, -C, and -DRB1, whereas high-resolution HLA typing
was used after 2006. Sibling donors with HLA-A, -B, -C and -DRB1 8/
8ematched related donors were deﬁned as matched related donors. For
unrelated transplantation, HLA-A, -B, -C, and DRB1 8/8ematched unrelated
donors were deﬁned as matched unrelated donors, and transplantation
from HLA-A, -B, -C, and -DRB1 7/8 or 6/8ematched unrelated donors was
deﬁned as mismatched unrelated donors. The conditioning regimens were
classiﬁed as myeloablative if total body irradiation > 8 Gy (n ¼ 22), oral
busulfan  9 mg/kg, or intravenous busulfan  7.2 mg/kg (n ¼ 67) was
included in the conditioning regimen, whereas other conditioning regimens
were classiﬁed as reduced-intensity conditioning regimens. Informed consent
for genetic analyses of the samples taken at the time of diagnosis was ob-
tained from all subjects. This study was approved by the institutional review
board of Chonnam National University, Hwasun Hospital, Korea.
Gene Mutation Analyses
Cryopreserved bone marrow or peripheral blood samples taken at
diagnosis were archived, and genomic DNA was extracted using QIAamp
DNA blood mini-kits (Qiagen, Valencia, CA), following the manufacturer’s
protocol. The mutation analysis was performed using Sanger sequencing
and a PCR methodology. TET2, FLT3-ITD, and nucleophosmin 1 (NPM1)
mutation testing was performed as described previously [28,29]. TET2
missense mutations were included in the analysis only when they were
located within 1 of 2 evolutionarily conserved domains (amino acids 1104 to
1478 or 1845 to 2002); identical TET2mutations in both alleles were deﬁned
as homozygous [30,31]. The DNMT3A, Wilms tumor gene 1 (WT1), neuro-
blastoma RAS viral oncogene homolog (NRAS), additional sex combs like
transcriptional regulator 2 (ASXL2), and IDH1/2 mutation analyses were
performed as reported previously [30-36]. CCAAT/enhancer binding protein
a (CEBPA), FAT Atypical Cadherin 1 (FAT1), dynein axonemal heavy chain 11
(DNAH11), and guanine-adenine-thymine-adenine 2 (GATA2) were ampli-
ﬁed by genomic PCR; overlapping PCR products covering the entire coding
sequence were generated and sequenced using the PCR primers shown in
Table S1. Ampliﬁcation featured initial denaturation at 95C for 5 minutes,
followed by 40 cycles of 94C for 30 seconds, 62C for 30 seconds, and 72C
for 1 minute, and a ﬁnal extension at 72C for 10 minutes. The ampliﬁcation
products were sequenced on an ABI 3100 platform using a cycle sequencing
kit (BigDye Terminator, Applied Biosystems, Foster City, CA).
Response and Survival Endpoints
The deﬁnition of complete remission (CR) followed recommended
criteria [37]. Relapse incidence (RI) was deﬁned as the time from the date of
allogeneic HCT to the date of relapse in all patients, considering competing
risks of death without relapse. Nonrelapse mortality (NRM) was deﬁned as
death occurring in the absence of relapse. Event-free survival (EFS) was
deﬁned as the time from the date of allogeneic HCT to the date of death from
any cause or relapse, whichever occurred ﬁrst. Overall survival (OS) was
deﬁned as the time from the date of allogeneic HCT to the date of last follow-
up or death from any cause. Acute graft-versus-host disease (aGVHD) and
chronic graft-versus-host disease (cGVHD) grading were recorded as
described previously [38,39].
Statistical Analysis
Descriptive statistics are presented as frequencies with percentages for
categorical variables and as medians with ranges for continuous variables.
Clinical characteristics and treatment outcomes were compared with each
mutation. The chi-square test was used to compare differences in the cat-
egorical data distributions and the Student t-test was used to evaluate dif-
ferences between continuous variables.
EFS and OS were calculated using the Kaplan-Meier method, and dif-
ferences among groups were compared using the log-rank test for the
univariate analysis and the Cox’s proportional hazard model for the multi-
variate analysis. cGVHD was treated as a nonetime-dependent covariate.
The incidences of relapse, NRM, aGVHD, and cGVHD were calculated using
the cumulative incidence method, considering competing risks. Gray’s test
was used for univariate comparisons and the Fine-Gray test was used for
multivariate comparisons [40]. A backward step-wise selection procedure
was used for the ﬁnal model construction in the multivariate analysis, in
which covariates with P values < .10 in the univariate analysis were
included. P values < .05 were considered to indicate signiﬁcance. Hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) were estimated using a
predetermined reference risk unity value.
Signiﬁcantly lower outcomes were noted in the group with the FLT3-
ITDpos/DNMT3A R882mut when compared with those in the other groups.
However, as expected, there was an imbalance in the pretransplantation
characteristics between the 2 groups, which necessitated excluding the ef-
fects of other imbalanced confounding variables, except mutation status.
Pretransplantation clinical factors were included in the propensity score
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groups. The propensity scorewas calculated using a linear regression model,
including age, sex, conditioning, donor type, CR duration until allogeneic
HCT, white blood cell (WBC) count at diagnosis, stem cell source, and T cell
depletion. Then, a 1:2 matching procedure was performed to match be-
tween patients with the FLT3-ITDpos/DNMT3A R882mut versus the others,
using a delta selection cutoff of .20 as the propensity score difference. In this
study cohort, suitable matching controls for 1 patient could not be found
using these criteria in the 1:2 matching procedure and this patient was,
therefore, excluded from the analysis. In total, 30 patients were selected for
the 1:2 analysis.
All statistical analyses were performed using SPSS ver. 21.0 software




Baseline patients and clinical characteristics are summa-
rized in Table S2. A total of 115 patients underwent allogeneic
HCT in CR1. Themedian age of patients at allogeneic HCT was
42 (range, 15 to 64) years and 57 patients (49.6%) were male.
Allogeneic transplant sources were matched related donors
(n¼66),matchedunrelateddonors (n¼34), andmismatched
unrelated donors (n¼ 15). In total, 80.9% of patients received
allogeneic HCT after 2006. Eighty-nine patients received
myeloablative conditioning and 26 subjects received either
nonmyeloablative or reduced-intensity conditioning regi-
mens. The stem cell sources were bone marrow (n ¼ 27) and
peripheral blood stem cells (n ¼ 88). In vivo T cell depletion
was performed in 30 patients (26.1%) using either antithy-
mocyte globulin (n¼ 17) or alemtuzumab (n¼ 13) treatment.
Mutation Frequencies
Of the 115 patients, DNMT3Amut was detected in 36 pa-
tients (31.3%). The most common DNMT3Amut site was R882.
Twenty-one patients had DNMT3A R882mut; ie, R882H
(n ¼ 15), R882C (n ¼ 5), and R882S (n ¼ 1), whereas 15 pa-
tients had non-R882 DNMT3Amut. One patient had a double
DNMT3A gene mutation (R366H and F755S). Thirteen
different types of TET2mut were detected in 10 patients (8.7%),
including 3 nonsense, 5 frameshift, and 5 missense muta-
tions. TET2 gene double mutations were detected in 3 pa-
tients, and a homozygous TET2 mutation was observed in 1
patient. Three patients had an IDH1mut in codon 132, whereas
16 patients had an IDH1mut in codon 140 (n¼ 14) or codon 172
(n ¼ 2). The prevalences of the other mutations were as
follows: FLT3-ITDpos (32.2%), NPM1 mutation (NPM1mut;
43.5%), CEPBA double mutation (CEBPAdm; 24.6%), WT1 mu-
tation (WT1mut; 14.8%), NRASmutation (NRASmut; 6.1%), FAT1Figure 1. Schematic representation of the mutational status of patients wmutation (FAT1mut; 7.0%), ASXL2 mutation (ASXL2mut; 4.5%),
DNAH11 mutation (1.7%), and GATA2 mutation (GATA2mut,
1.8%). Details of the epigenetic modifying genes mutations
and their locations are described in Figure S2.Associations between the Mutations and Patients’
Clinical Characteristics
The epigenetic modifying genes (DNMT3A, TET2, and
IDH1/2) and their associations with other molecular muta-
tions (FLT3-ITD, NPM1, CEBPA, WT1, NRAS, ASXL2, FAT1,
DNAH11, GATA2) are described in Figure 1. DNMT3Amut was
mutually exclusive with CEBPAdm (P ¼ .008), whereas
DNMT3Amut showed positive correlation with NPM1mut
(P < .001) and, FAT1mut (P ¼ .006). The DNMT3A R882 muta-
tion (DNMT3A R882mut) was also associated with FLT3-ITDpos
(P ¼ .028), NPM1mut (P < .001), and FAT1mut (P ¼ .016). No
mutual expression of the TET2mut or IDH1/2mut was observed
with the other mutations. FLT3-ITDpos had a higher coinci-
dence with NPM1mut (P ¼ .005) and patients with CEBPAdm
were highly unlikely to have FLT3-ITDpos (P ¼ .001) or
NPM1mut (P < .001). NPM1mut was correlated with GATA2mut
(P¼ .013).WT1mutwas associatedwithNRASmut (P¼ .031) and
DNAH11 mutation was associated with ASXL2mut (P ¼ .002).
Patients’ clinical characteristics were signiﬁcantly asso-
ciated with the mutations. In this cohort, DNMT3Amut (odds
ratio [OR], 1.071; 95% CI, 1.031 to 1.113), DNMT3A R882mut
(OR, 1.077; 95% CI, 1.026 to 1.131), and NPM1mut (OR, 1.048;
95% CI, 1.015 to 1.082) were associated with increasing age.
FLT3-ITDpos was signiﬁcantly associated with elevated WBC
count at diagnosis (P ¼ .022).Transplantation Outcomes according to Clinical Factors
The baseline patient characteristics are listed in Table S2.
Of the 115 patients, 66 patients (57.4%) received HCT using a
matched related donor. Peripheral blood stem cells were
given to 88 patients (76.5%) and 89 patients (77.4%) received
myeloablative conditioning. Twenty-seven patients (23.5%)
relapsed and 49 patients (42.6%) died, either from relapse
(n ¼ 27, 23.5%) or from other causes (n ¼ 22, 19.1%), with a
median follow-up of 75.7 months (range, 10.8 to
179.8 months) among survivors. The 5-year OS and EFS rates
were 57.3% (95% CI, 48.1 to 66.5) and 58.1% (95% CI, 48.9 to
67.3), respectively, whereas the 5-year RI rate was 23.1% (95%
CI, 15.8 to 31.3). Clinical risk factors were evaluated for OS
and EFS, but no signiﬁcant clinical risk factor affected OS or
EFS (Table 1). A higher risk of relapse was observed inith NK-AML at diagnosis. Colored grids indicate mutation positive.
Table 1
Univariate and Multivariate Analyses of Clinical and Mutational Status of 121 Patients with NK-AML
Risk Factor Status OS EFS
Univariate Multivariate Univariate Multivariate













All patients 115 (100) 57.3 58.1
Age, yr* .191 - .265 -
WBC at diagnosis* .101 - .058 -
Donor type Matched sibling 66 (57.4) 62.0 .185 - 62.4 .293 -
Others 49 (42.6) 50.6 52.5
Source Bone marrow 27 (23.5) 54.7 .958 - 54.9 .871 -
PBSC 88 (76.5) 58.2 59.3
Conditioning Myeloablative 89 (77.4) 58.9 .491 - 60.0 .461 -
Reduced intensity 26 (22.6) 51.2 51.4
T cell depletion No 85 (73.9) 56.4 .861 - 55.6 .824 -
Yes 30 (26.1) 59.4 59.4
Year at allogeneic HCT <2006 22 (19.1) 54.5 .939 - 54.5 .921 -
2006 93 (90.9) 56.7 57.8
cGVHD No 63 (54.8) 53.4 .304 - 53.8 .148 -
Yes 52 (45.2) 62.8 64.3
FLT3-ITD Positive 37 (32.2) 40.2 .007 .018 1.990
(1.125-3.521)
40.4 .003 .006 2.230 (1.258-3.953)
Wild-type 78 (67.8) 65.3 1.000 66.6 1.000
NPM1 Mutated 50 (43.5) 57.7 .873 - 59.3 .949 -
Wild-type 65 (56.5) 56.7 57.1
CEBPA Double mutated 28 (24.6) 66.7 .351 - 67.5 .345 -
Others 86 (75.4) 53.4 54.5
DNMT3A R882 Mutated 21 (18.3) 33.3 .002 .006 2.428
(1.294-4.555)
33.3 .001 .002 2.740 (1.461-5.142)
Others 94 (81.7) 62.6 1.000 63.7 1.000
TET2 Mutated 10 (8.7) 50.0 .563 - 50.0 .546 -
Wild-type 105 (91.3) 57.8 58.8
IDH1/2 Mutated 19 (16.5) 56.9 .974 - 61.0 .670 -
Wild-type 96 (83.5) 57.1 57.2
WT1 Mutated 17 (14.8) 47.1 .260 - 47.1 .309 -
Wild-type 98 (85.2) 59.0 60.1
FAT1 Mutated 8 (7.0) 33.3 .111 - 33.3 .083 -
Wild-type 107 (93.0) 58.8 59.8
NRAS Mutated 7 (6.1) 85.7 .149 - 85.7 .162 -
Wild-type 108 (93.9) 55.2 56.2
Parameter Status NRM RI
Univariate Multivariate Univariate Multivariate













All patients 115 (100) 20.7 23.1
Age, yr* .030 .044 1.046
(1.001-1.092)
.294 -
WBC at diagnosis* 19.9 1.000 - <.001 .005 1.000 (1.000-1.000)
Donor type Matched sibling 66 (57.4) 17.5 .558 - 20.0 .366 -
Others 49 (42.6) 22.8 28.8
Source Bone marrow 27 (23.5) 18.7 .710 - 26.4 .767 -
PBSC 88 (76.5) 21.4 21.9
Conditioning Myeloablative 89 (77.4) 25.9 .070 .019 1.000 18.3 .020 .026 1.000
Reduced intensity 26 (22.6) 8.3 .181 (.044-.526) 40.3 2.969 (1.139-7.739)
T cell depletion No 85 (73.9) 22.0 .535 - 22.7 .956 -
Yes 30 (26.1) 16.7 23.3
Year at allogeneic HCT <2006 22 (19.1) 27.3 .478 - 18.2 .495 -
2006 93 (90.9) 20.3 23.9
cGVHD No 63 (54.8) 8.1 <.001 .031 1.000 38.8 <.001 .021 1.000
Yes 52 (45.2) 33.8 3.830
(1.478-9.924)
5.8 .154 (.047-.507)
FLT3-ITD Positive 37 (32.2) 13.9 .156 - 48.8 <.001 <.001 4.801 (2.239-10.290)
Wild-type 78 (67.8) 23.8 10.8 1.000
NPM1 Mutated 50 (43.5) 22.7 .830 - 22.0 .993 -
Wild-type 65 (56.5) 19.0 24.1
CEBPA Double mutated 28 (24.6) 24.6 .969 - 14.7 .211 -
Others 86 (75.4) 20.5 27.1
DNMT3A R882 Mutated 21 (18.3) 19.0 .806 - 47.6 <.001 .046 2.393 (1.017-5.629)
Others 94 (81.7) 21.0 17.6 1.000
TET2 Mutated 10 (8.7) 30.0 .425 - 20.0 .763 -
Wild-type 105 (91.3) 19.8 24.2
IDH1/2 Mutated 19 (16.5) 19.0 .463 - 23.4 .826 -
Wild-type 96 (83.5) 19.9 24.1
(Continued on next page)
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Table 1
(continued)
Parameter Status NRM RI
Univariate Multivariate Univariate Multivariate













WT1 Mutated 17 (14.8) 17.6 .756 - 35.3 .198 -
Wild-type 98 (85.2) 21.1 21.0
FAT1 Mutated 8 (7.0) 45.8 .226 - 37.5 .213 -
Wild-type 107 (93.0) 19.1 22.0
NRAS Mutated 57 (49.6) 0 .160 - 14.3 .552 -
Wild-type 58 (50.4) 22.0 23.7
PBSC indicates peripheral blood stem cells; FLT3-ITD, fms-related tyrosine kinase 3-internal tandem duplication; NPM1, nucleophosmin 1; CEBPA, CCAAT/
enhancer binding protein a; DNMT3A R882, DNA methyltransferase 3A R882; TET2, ten-eleven-translocation oncogene family member 2; IDH1/2, isocitrate
dehydrogenase 1/2; WT1, Wilms tumor gene 1; FAT1, FAT Atypical Cadherin 1; NRAS, neuroblastoma RAS viral oncogene homolog.
* Age was calculated for continuous variables to evaluate the risk using Cox’s proportional hazard model and Gray’s test.
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intensity conditioning (versus myeloablative conditioning),
and no cGVHD (versus development of cGVHD) (Table 1).
DNMT3A R882mut and FLT3-ITDpos Adversely Affect
Transplantation Outcomes after Allogeneic HCT in
Patients with NK-AML
Next, we analyzed transplantation outcomes according to
the mutations. Patients with FLT3-ITDpos showed inferior OS
andEFS andhigher RI comparedwith thosewithout FLT-ITD (P
< .05) (Figure S3). DNMT3Amut was associated with inferior
EFS (P ¼ .042) and higher RI (P ¼ .033) but revealed a
borderline difference for OS (P ¼ .060). No differences in OS,
EFS, orRIwere observed inpatientswithTET2mut or IDH1/2mut.
Then, outcomes were reanalyzed in detail according to
the DNMT3Amut location, and the worst outcomes were
found in the group with DNMT3A R882mut. The 5-year OS
rates in patients with the DNMT3A wild-type versus non-
R882 DNMT3Amut versus DNMT3A R882mut were 62.4% (95%
CI, 51.4 to 73.4) versus 64.3% (95% CI, 39.2 to 89.3) versus
33.3% (95% CI, 18.1 to 53.4), respectively. The 5-year EFS rates
were 62.3% (95% CI, 51.5 to 73.1) versus 64.6% (95% CI, 39.5 to
89.7) versus 33.3% (95% CI, 14.5 to 52.1), whereas the 5-year
RI rates were 18.3% (95% CI, 10.5 to 27.8) versus 13.8% (95% CI,
2.0 to 36.7) versus 47.6% (95% CI, 24.9 to 67.3), respectively
(Figure 2). Of note, the group with non-R882 DNMT3Amut
showed similar transplantation OS, EFS, and RI outcomes
as those with wild-type DNMT3A. Therefore, we chose
DNMT3A R882mut as a signiﬁcant prognostic factor for further
analyses.Figure 2. Prognostic impact on patients with NK-AML after allogeneic HCT. (A) OS,NRM and GVHD
Of 115 patients, any aGVHD grade was observed in 44
patients (38.3%) and any cGVHD grade, according to the
National Institutes of Health consensus criteria, was
observed in 67 patients (58.2%). The cumulative incidence
rates of aGVHD (grades 2 to 4) and cGVHD (moderate
grade) were 29.7% (95% CI, 21.6 to 38.3) at 100 days and 46.1%
(95% CI, 36.5 to 55.1) at 5 years, respectively. In a multivariate
analysis, a matched related donor (HR, .394; 95% CI, .197 to
.787; P ¼ .008) decreased the risk for aGVHD. However,
mutational status did not affect either the risk for acute or
chronic GVHD (data not shown).
The 5-year NRM rate was 20.7% (95% CI, 14.0 to 29.3) in
the overall population. No difference in NRM according to
any mutation was noted (Table 1). In multivariate analysis,
cGVHD increased the risk of NRM (HR, 3.830; 95% CI, 1.478 to
9.924; P ¼ .031) and reduced-intensity conditioning (HR,
.181; 95% CI, .044 to .526; P¼ .019) decreased the risk of NRM
(Table 1).
Multivariate Analysis for OS, EFS, and Relapse
The multivariate analysis results are shown in Table 1.
FLT3-ITDpos and DNMT3A R882mut were signiﬁcant risk fac-
tors for OS; patients with FLT3-ITDpos had a 2-fold (HR,1.990;
95% CI,1.125 to 3.521; P¼ .018) higher risk of death compared
with that of patients with the wild-type, whereas those with
DNMT3A R882mut had a 2.4-fold (HR, 2.428; 95% CI, 1.294 to
4.555; P ¼ .006) higher risk of death than that those with
wild-type or non-R882 DNMT3Amut. Patients with FLT3-ITD-
pos and DNMT3A R882mut had 2.2- (HR, 2.23; 95% CI, 1.258 to(B) EFS, and (C) RI according to the DNMT3A mutations and their locations.
J.-S. Ahn et al. / Biol Blood Marrow Transplant 22 (2016) 61e70663.935; P¼ .006) and 2.7- (HR, 2.74; 95% CI, 1.461 to 5.142; P¼
.002) fold higher risks for each EFS event. In addition, FLT3-
ITDpos, DNMT3A R882mut, high WBC at diagnosis, and
reduced-intensity conditioning were signiﬁcantly associated
with a higher risk for relapse, whereas cGVHD reduced the
risk of relapse in a multivariate analysis: patients with FLT3-
ITDpos showed a 4.8-fold higher risk of relapse than those
who were negative for FLT3-ITD (HR, 4.801; 95% CI, 2.239 to
10.29; P < .001), and patients with DNMT3A R882mut showed
a 2.4-fold higher risk of relapse than those with wild-type or
non-R882 DNMT3Amut (HR, 2.393; 95% CI, 1.017 to 5.629; P ¼
.046). Reduced-intensity conditioning (HR, 2.969; P ¼ .026)
and highWBC count (HR,1.0; P¼ .005) also increased the risk
of relapse. Development of cGVHD decreased the risk of
relapse risk by 85% (HR, .154; P ¼ .021) compared with those
without cGVHD. A multivariate analysis showed that TET2mut
and IDH1/2mut did not affect OS, EFS, or RI.Comparison of Transplantation Outcomes according to
DNMT3A R882mut Accompanied by FLT3-ITDpos
We divided the patients into subgroups according to Eu-
ropean LeukemiaNet risk, based on FLT3-ITD positivity and
the status of the other mutations. We reanalyzed the clinical
outcomes based on DNMT3A R882mutational status (Table 2,
S3). In the poor prognostic subgroup, such as European
LeukemiaNet intermediate-I or FLT3-ITDpos, DNMT3A
R882mut was a signiﬁcant risk factor for worse OS, EFS, and RI
outcomes (Table 2). In OS, EFS, and RI, patients with FLT3-
ITDpos/DNMT3A R882mut had signiﬁcantly worse outcomes
compared with patients with FLT3-ITDneg/DNMT3A R882wild,
FLT3-ITDneg/DNMT3A R882mut, and FLT3-ITDpos/DNMT3A
R882mut (all, P < .05) (Figure 3). Eleven patients had both
FLT3-ITDpos and DNMT3A R882mut, whereas 104 patients
showed only either FLT3-ITDpos or DNMT3A R882mut or the
wild-type in both genes. The FLT3-ITDpos/DNMT3A R882mut
group had a signiﬁcantly higher RI but lower OS and EFS than
those with the other mutations (P < .05) (Table 3).
However, it was also possible that the unfavorable fea-
tures of patients harboring FLT3-ITDpos/DNMT3A R882mut
were due to other clinical risk factors affecting treatment
outcome. For example, the FLT3-ITDpos/DNMT3A R882mut
group had a higher proportion of high WBC counts at pre-
sentation compared with those with the other mutations
(P ¼ .081) (Table 3), which may have led to worse trans-
plantation outcomes. Thus, we conducted a 1:2 matched
analysis to remove potential confounding variables affecting
outcome besides the genetic factors.
A propensity score was calculated and matched as a 1:2
pair according to the genetic group (ie, FLT3-ITDpos/DNMT3A
R882mut versus others). This pair was matched for allTable 2
Clinical Outcomes according to DNMT3A R882 Mutational Status in the ELN Risk G
DNMT3A R882 n 5-Yr OS,
% (95% CI)
P Value 5-Yr EFS
% (95% C
ELN Favorable Others* 46 68.6 (54.9-82.3) .429 70.8 (57.
Mutated 9 55.6 (23.1-88.1) 55.6 (23.
ELN Intermediate-I Others* 48 56.8 (42.5-71.1) <.001 57.0 (42.
Mutated 12 16.7 (.0-37.9) 16.7 (.0-
FLT3-ITDneg Others* 68 66.2 (54.6-77.8) .598 67.6 (56.
Mutated 10 60.0 (29.6-90.4) 60.0 (29.
FLT3-ITDpos Others* 26 53.3 (33.9-72.7) .001 53.6 (34.
Mutated 11 9.1 (.0-26.3) 9.1 (.0-
ELN indicates European LeukemiaNet.
* Others, patients with the non-R882 DNMT3Amut or DNMT3A wild-type.pretransplantation risk factors; thus, all confounding effects
were removed from those variables. In total, 30 patients were
selected for 1:2 matching analysis (Table 3). T cell depletion
varied between the FLT3-ITDpos/DNMT3A R882mut group and
the others before the 1:2 match; however, it was similar after
the 1:2 match and the difference between the WBC counts
also decreased. In the 1:2 matched analysis, the FLT3-ITDpos/
DNMT3A R882mut group had signiﬁcantly higher RI (HR,
5.036; 95% CI, 1.689 to 15.020; P ¼ .004) and lower OS (HR,
4.007; 95% CI, 1.472 to 10.909; P ¼ .007) and EFS (HR, 4.760;
95% CI, 1.733 to 13.073; P ¼ .002) compared with those in the
other groups (Figure 4).DISCUSSION
We examined the prognostic impact of epigenetic modi-
fying genemutations on allogeneic HCToutcomes in patients
with NK-AML. Of 3 epigenetic mutations (DNMT3A, TET2, and
IDH1/2), DNMT3A, particularly that located at residue R882,
showed a signiﬁcantly worse prognosis for OS, EFS, and RI
after allogeneic HCT in patients with NK-AML. Patients with
NK-AML and DNMT3A R882mut accompanied by FLT3-ITDpos
showed the worst outcome, even after allogeneic HCT.
A comprehensive analysis of genetic modiﬁcations in
patients with AML identiﬁed the recurrent mutations
involved in epigenetic regulation of transcription [41-43].
The DNMT3A, TET2, and IDH1/2 mutations, which result in
alterations in DNA methylation, are the most commonly
occurring mutations found in patients with AML, particularly
those with NK-AML [41,42]. Many studies have shown the
negative impact of DNMT3Amut on outcomes, such as CR, OS,
EFS, and RI [8,9,44]. The negative impact of DNMT3Amut on
prognosis is augmented in speciﬁc molecular high-risk
groups [9,45]. Although the biochemical impact of IDH1/
2mut has been well described, the prognostic impact of IDH1/
2mut remains heterogeneous among studies according to the
population involved [42,46-48]. In addition, the prognostic
role of TET2mut in patients with NK-AML is also controversial.
A meta-analysis reported that TET2mut in patients with NK-
AML negatively affects the OS and EFS prognosis [24].
However, the prognostic signiﬁcance of these 3 epigenetic
modifying genes in combination in patients with NK after
allogeneic HCT has not been analyzed.
The majority of DNMT3Amut are missense mutations that
occur most frequently at residue R882. The high frequency of
mutations at this speciﬁc site suggests dominant-negative
consequences [49]. DNMT3A R882mut causes a striking
reduction in de novo DNMT activities, compared with that of
non-R882 DNMT3Amut [49]. However, the clinical signiﬁ-
cance of DNMT3A R882mut in patients with AML is unclear
[8]. Ribeiro et al. reported that R882mutations are associatedroup with FLT3-ITD Positivity
,
I)
P Value 5-Yr NRM,
% (95% CI)
P Value 5-Yr Relapse,
% (95% CI)
P Value
2-84.3) .363 19.9 (9.7-32.7) .453 11.2 (4.0-22.4) .963
1-88.1) 33.3 (6.5-64.3) 11.1 (5.0-40.6)
7-66.8) <.001 21.7 (11.1-34.7) .320 23.8 (12.6-36.9) <.001
37.9) 8.3 (.2-36.5) 75.0 (36.3-92.2)
0-79.1) .541 22.9 (13.5-33.7) .643 10.9 (4.7-20.0) .997
6-90.4) 30.0 (6.1-59.5) 10.0 (5.0-37.4)
4-72.8) <.001 16.0 (4.8-33.2) .613 34.9 (17.2-53.3) <.001
26.3) 9.1 (.1-42.0) 81.8 (36.7-96.1)
Figure 3. Prognostic impact on patients with NK-AML after allogeneic HCT. (A) OS, (B) EFS, and (C) RI according to FLT3-ITD and DNMT3A R882 mutational status.
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with an R882 mutation have a worse prognosis in terms of
relapse-free survival, particularly those in the NK-AML sub-
group [6,45]. However, contradictory ﬁndings have been
reported: Marcucci et al. found that R882 mutations do not
adversely affect survival in younger patients with NK-AML
[7].
Thol et al. determined the prognostic effect of DNMT3A
mutational status on OS after allogeneic HCT. The 5-year OS
in patients with NK-AML and a related donor was 59% in the
DNMT3Amut group (n¼ 18) versus 50% in thewild-type group
(n ¼ 44). However, that study was limited to a small number
of cases and the authors did not statistically compare survival
according to the DNMT3Amut after allogeneic HCT in patients
with NK-AML. Additionally, the authors did not distinguish
the location of the DNMT3Amut (R882 mutation versus non-
R882 mutation) in their analysis [9]. In our cohort, patients
with the non-R882 DNMT3Amut showed similar survival and
relapse risk outcomes as those with DNMT3 wild-type, and
only DNMT3A R882mut was associated with poor OS, EFS, and
RI prognoses in the multivariate analysis. Based on our
ﬁndings, we speculate that non-DNMT3A R882mut does not
adversely affect survival after allogeneic HCT in patients with
NK-AML and that DNMT3A R882mut carries a poor prognostic
impact on survival and relapse in patients with NK-AML who
undergo allogeneic HCT.Table 3
Clinical Characteristics and Transplantation Outcomes of Patients with NK-AML, FL
Characteristics All Patients, n (%)
FLT3-ITDpos/
DNMT3A R882mut
(n ¼ 11) (%)
Others*
(n ¼ 104) (%)
Age, median (range), yr 44 (26-61) 42 (15-64)
WBC at diagnosis, median (range), /L 46.7 (36.2-279.0) 25.6 (.9-397.2)
Male 6 (54.5) 51 (49.0)
Myeloablative conditioning 7 (63.6) 82 (78.8)
Matched sibling donor 4 (36.4) 62 (59.6)
CR duration until allogeneic HCT,
median (range), months
3.9 (2.3-16.8) 2.9 (.9-9.7)
Source (BM) 3 (27.3) 24 (23.1)
T cell depletion 6 (54.5) 24 (23.1)
5-Yr OS, % (95% CI) 9.1 (.0-26.2) 62.3 (52.7-71.9)
5-Yr EFS, % (95% CI) 9.1 (.0-26.2) 63.3 (53.9-72.7)
5-Yr NRM, % (95% CI) 9.1 (.1-42.0) 21.9 (14.3-30.5)
5-yr RI, % (95% CI) 81.8 (36.7-96.1) 16.9 (10.3-24.9)
Diff indicates standardized mean difference; BM, bone marrow; NA, not applicable
* Others, patients with only FLT3-ITD positivity or the DNMT3A R882 mutation oMany previous studies support the ﬁnding that allogeneic
HCT does not override the poor prognostic feature of FLT3-
ITDpos [50-52], suggesting that patients with FLT3-ITDpos
experience a higher risk of relapse and worse survival, even
after allogeneic HCT. Our study also replicated a similar
ﬁnding that the FLT3-ITDpos group had worse survival after
HCT than those without FLT3-ITD.
Such epigenetic modifying gene mutations are known as
early genetic events in myeloid malignancies [13,53,54]. One
study reported that epigenetic modifying gene mutations
might cause genetic instability, leading to therapeutic resis-
tance and relapse [14]. Our results indicate that early genetic
instability accompanying DNMT3A R882mut may increase the
risk of relapse in patients receiving allogeneic HCT. There-
fore, pretransplantation DNMT3A R882mut is a strong prog-
nostic factor predicting a high risk of relapse after allogeneic
HCT. A genetic analysis of paired initial and relapse samples
would help identify the mechanisms underlying AML
relapse. Wakita et al. discovered that epigenetic modifying
gene mutations lead to genetic instability, thereby promot-
ing expansion of FLT3-ITDpos clones [14]. Our results support
the notion that co-occurrence of DNMT3A R882mut and
FLT3-ITDpos potentiates the aggressiveness of leukemic cells,
suggesting that DNMT3A R882mut could be used to stratify
patients with FLT3-ITDpos according to their prognosis, even
after allogeneic HCT.T3-ITD Positivity, and the DNMT3A R882 Mutation versus the Others





(n ¼ 10) (%)
Others*




.282 .343 42 (26-57) 44 (20-64) .877 .065
.081 .558 46.7 (36.2-279.0) 71.7 (2.0-173.7) .502 .263
.728 .090 6 (60.0) 10 (50.0) .605 .042
.251 .078 7 (70.0) 12 (60.0) .592 .037
.138 .150 4 (40.0) 8 (40.0) 1.000 .085
.240 .374 3.5 (2.3-16.8) 4.4 (2.4-9.7) .916 .041
.755 .200 2 (20.0) 5 (25.0) .760 .259
.024 .077 5 (50.0) 10 (50.0) 1.000 .065
<.001 NA 10.0 (.0-28.6) 65.0 (44.0-86.0) .003 NA
<.001 NA 10.0 (.0-28.6) 65.0 (44.0-86.0) .004 NA
.317 NA 10.0 (.2-41.7) 10.0 (1.6-27.9) .967 NA
<.001 NA 80.0 (29.3-96.0) 25.0 (8.7-45.4) .004 NA
.
r wild-type for both.
Figure 4. Outcomes of patients undergoing HCT according to FLT3-ITD positivity and DNMT3 R882 mutational status. OS (A, B), EFS (C, D), and RI (E, F), in all patients
(A, C, and E), and 1:2 paired patients (B, D, and F) are shown. “Others” includes patients with only FLT3-ITD positivity, a DNMT3A R882 mutation, or wild-type for both.
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ered when interpreting the clinical signiﬁcance of epigenetic
modifying gene mutations. First, mutational status was
analyzed once at diagnosis. Therefore, we have no further
information about serial changes in mutational status at
transplantation or relapse. Second, we did not include a
donor versus no-donor comparison, so we cannot say which
treatment (allogeneic HCT versus chemotherapy only) mo-
dality provided better survival in patients with non-R882
DNMT3Amut. However, our results have signiﬁcant clinical
relevance, as a full epigenetic modifying gene mutation
dataset and long-term follow-up information after allogeneic
HCT are now available. The population was restricted exclu-
sively to patients with NK-AML alone. Additionally, data from
the propensity score matching analysis using the well-
matched paired group consistently support our ﬁnding that
co-occurrence of FLT3-ITDpos/DNMT3A R882mut is a poor risk
factor in patients with NK-AML, even after allogeneic HCT.
In conclusion, DNMT3A R882mut, particularly when
accompanied by FLT3-ITDpos, had a signiﬁcant prognostic
impact on survival and relapse rates in patients with NK-AML
after allogeneic HCT. In contrast, non-R882 DNMT3Amut did
not inﬂuence transplantation outcomes.
Additional studies are required to explore the kinetics of
mutant allele frequencies and the status of other mutations
at relapse to clarify the role of DNMT3A R882mut with FLT3-
ITDpos in the transplantation setting. Further studies with
larger numbers of patients are warranted to reach clearer
conclusions.
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